Correction: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma

被引：0

作者：

Astrid Lièvre

Bérèngere Ouine

Jim Canet

Aurélie Cartier

Yael Amar

Wulfran Cacheux

Odette Mariani

Rosine Guimbaud

Janick Selves

Thierry Lecomte

Serge Guyetant

Ivan Bieche

Frédérique Berger

Leanne de Koning

机构：

[1] CHU Pontchaillou,Service des maladies de l’appareil digestif

[2] Université Rennes 1,Faculté de médecine

[3] Rue Bataille Flandres-Dunkerque,Inserm ER440

[4] Institut Curie,Oncogenesis, Stress and Signaling

[5] PSL Research University,Department of Translational Research

[6] PSL Research University,Institut Curie

[7] Unit of Biostatistics,Department of Medical Oncology, Institut Curie

[8] René Huguenin Hospital,Department of Genetics, Institut Curie

[9] Unit of Pharmacogenomics,Biological Resource Center, Institut Curie

[10] PSL Research University,Centre de Recherche en Cancérologie de Toulouse, Unité Mixte de Recherche

[11] 26 rue d’Ulm,Service d’oncologie médicale

[12] 1037 INSERM—Université Toulouse III,Department of Pathology

[13] Centre Hospitalier Universitaire de Toulouse,Hôpital Trousseau—CHRU de TOURS

[14] Centre Hospitalier Universitaire de Toulouse,UMR CNRS 7292 (GICC)

[15] Service d’Hépato-Gastro-Entérologie,Hôpital Trousseau—CHRU de TOURS

[16] Université François Rabelais,Institut Curie

[17] Service d’Anatomie et Cytologie Pathologiques—Tumorothèque,undefined

[18] PSL Research University,undefined

[19] INSERM U900,undefined

来源：

British Journal of Cancer | 2018年 / 119卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Supplementary Table 1 and the Supplementary Figure legends were not included when this manuscript was first published. The files are now available here.

引用

页码：387 / 387

共 50 条

[41] BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer
Chen Mao
Ru-Yan Liao
Qing Chen
Journal of Cancer Research and Clinical Oncology, 2010, 136 : 1293 - 1294
[42] BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer
Mao, Chen
Liao, Ru-Yan
Chen, Qing
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (08) : 1293 - 1294
[43] PREDICTIVE MOLECULAR BIOMARKERS IN COLORECTAL CANCER: IS KRAS AND BRAF WILD TYPE STATUS REQUIRED FOR ANTI-EGFR THERAPY?
Marchoudi, N.
Joutei, H. Amrani Hassani
Jouali, F.
Fekkak, J.
Rhaissi, H.
ANTICANCER RESEARCH, 2014, 34 (10) : 6048 - 6048
[44] Evaluating the Optimal Sequence of Treatment With EGFR Inhibitors and Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer
Martins, Diana
Rodrigues, Jessica
Redondo, Patricia
Juliao, Ivo
Faustino, Catia
CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (03)
[45] The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside
Zaniboni, A.
Formica, V.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 233 - 244
[46] The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside
A. Zaniboni
V. Formica
Cancer Chemotherapy and Pharmacology, 2016, 78 : 233 - 244
[47] First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy?
Airoldi, Marco
Bartolini, Michela
Fazio, Roberta
Farinatti, Sara
Dapra, Valentina
Santoro, Armando
Puccini, Alberto
CURRENT ONCOLOGY REPORTS, 2024, 26 (11) : 1489 - 1501
[48] Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis
Palmieri, Lola-Jade
Buchler, Tomas
Meyer, Antoine
Veskrnova, Veronika
Fiala, Ondrej
Brabec, Petr
Baranova, Jana
Coriat, Romain
CANCERS, 2022, 14 (06)
[49] Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer
Yang, Jiao
Li, Shuting
Wang, Biyuan
Wu, Yinying
Chen, Zheling
Lv, Meng
Lin, Yayun
Yang, Jin
TUMOR BIOLOGY, 2016, 37 (09) : 11645 - 11655
[50] Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’
Andrew Rowland
Mafalda M Dias
Michael D Wiese
Ganessan Kichenadasse
Ross A McKinnon
Christos S Karapetis
Michael J Sorich
British Journal of Cancer, 2015, 113 : 1635 - 1635

← 1 2 3 4 5 →